Companion Diagnostic Tests in Oncology Market

Companion Diagnostic Tests in Oncology Market (Detection Technique - Protein Detection, DNA Detection (Polymerase Chain Reaction, Next Generation Sequencing, and In Situ Hybridization (Fluorescence In Situ Hybridization, and Chromogenic In Situ Hybridization)); Biomarker - EGFR, BRAF V600E, KRAS, and HER2; Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, and Melanoma; End User - Pharmaceutical and Biotechnology Companies, Medical Device Companies, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

The rising incidence of various types of cancers, especially breast and prostate cancer, has created new opportunities for growth within the global companion diagnostic tests for oncology market. There is tremendous demand for improved technologies within the field of oncology, and advancements in companion diagnostics has supported the growth of this domain. Medical research has continually focused on finding antidotes to the development of fatal cancers or tumours in the human body. Several of these researchers have tasted success in their endeavours. However, there lie several unmet needs within the domain of oncology. Considering this fact, it is expected that the investments of the medical industry in companion diagnostic tests would increase.

  • In addition to the stellar demand for cancer drugs, people are also demanding improved medical care and diagnostic facilities. A large population of people gets to know of their know during the last stages, and this leaves minimal scope for treatment. Therefore, the use of companion diagnostic tests for oncology help in diagnosing and detecting the presence of cancerous cell during the early stages of development. In times of current disruptions within healthcare, the relevance of oncology drugs and new diagnostic lines cannot be underestimated. The revenues index of the global companion diagnostic tests for oncology market is slated to improve in the years to follow.
  • Based on geography, the global companion diagnostic tests for oncology market is led by the medical fraternity of the US. The US has been at the forefront of advancements in medical and oncological testing. Furthermore, the medical and healthcare budget of the country has constantly increased.
  • The outbreak of the novel corona virus across the global have led several other medical diagnostic domains at the backseat. However, the constant need for proper cancer treatment has created humongous opportunities for market growth and maturity. 

Global Companion Diagnostic Tests in Oncology Market: Snapshot

The global companion diagnostic tests in oncology market is expected to register phenomenal pace owing to increasing adoption of new tests, and rising shift from blockbuster drugs to personalized medicines, and targeted therapies. Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer. Increasing focus on research and development by various pharmaceutical and biotechnology companies, along with medical device companies, and increasing funding and grants for cancer research by various government agencies have led to high adoption of companion diagnostic tests in oncology.  According to the research report, the global companion diagnostic tests in oncology market is expected to be worth US$13.6 bn by the end of 2025 from US$3.5 bn in 2016. During the forecast period of 2017 and 2025, the global market is projected to rise at a CAGR of 16.8%.

companion-diagnostic-tests-in-oncology-market

EGFR Biomarker to Remain Popular Amongst Pharmaceutical Companies

Among the biomarker segment, the EGFR biomarker segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. It is expected to register highest CAGR during the forecast period of 2017-2025, owing to major factors such as increasing incidence of lung cancer, and rising R&D in biomarker segment. The HER2 and KRAS biomarkers are expected to register high CAGR during the forecast period, due to increasing incidence of cancer, and rising adoption of biomarker by pharmaceutical companies and research institutes. Analysts expect that the EGFR biomarker segment will register a CAGR of 18.4% over the forecast period.

Among the cancer types segment, the breast cancer segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. However lung cancer segment is expected to register highest CAGR during the forecast period of 2017-2025, owing to increasing incidence of lung cancer in developing countries. This shift is attributable to the increased smoking and rising biomarker research for the lung cancer treatment. According to statistics from the World Health Organization (WHO), in 2013, an estimated 1.9 million new cases of lung cancer were diagnosed, and the stats reveled that less developed regions including the emerging countries such as China, India, and other countries, had the highest incidence of lung cancer, owing to rising smoking habits and poor air quality in these countries.

North America to Remain Dominant with Higher Acceptance of Technologies

Geographically, the global companion diagnostic tests in oncology market is segmented into North America, the Middle East and Africa, Asia Pacific, Europe, and Latin America. Analysts expect that North America will continue to dominate the global market due to the higher acceptance of technology in the region. Furthermore, better rate of diagnoses in the region is also likely to favor the regional market’s growth. By the end of 2025, the regional market is projected to account for a share of 37.5% in the global market. On the other hand, Asia Pacific is also expected to offer lucrative opportunities due to high rate of unmet medical needs in the emerging economies of the region.

Major players having presence in the global companion diagnostic tests in oncology market include F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others.   

The global companion diagnostic tests in oncology market is segmented as follows:

By Detection Technique

  • Protein Detection
  • DNA Detection
    • Polymerase Chain Reaction (PCR)
    • Next Gen Sequencing (NGS)
    • In Situ Hybridization
      • Fluorescence In Situ Hybridization (FISH)
      • Chromogenic In Situ Hybridization (CISH)
  • Others

by Biomarker

  • EGFR
  • KRAS
  • HER2
  • BRAF V600E
  • Others

by Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Melanoma
  • Others

by End Users

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Research Institutes
  • Others

by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

    1. Preface                
         1.1. Market Definition and Scope                
         1.2. Market Segmentation                
         1.3. Key Research Objectives                
         1.4. Research Highlights                

    2. Assumptions and Research Methodology                

    3. Executive Summary : Global Digital Companion Diagnostics Market                

    4. Market Overview                
         4.1. Introduction                
                4.1.1 Detection Technique Definition                
                4.1.2 Industry Evolution / Developments                
         4.2. Overview                
         4.3. Key Market Indicators                
         4.4. Market Dynamics                
                4.4.1 Drivers                
                4.4.2 Restraints                
                4.4.3 Opportunity                
         4.5. Global Digital Companion Diagnostics Market  Analysis and Forecasts, 2015–2025                
                4.5.1 Market Revenue Projections (US$ Mn)                
         4.6. Porter’s Five Force Analysis                
         4.7. Market Outlook                
         4.8. Future Trends: response-guided therapy, theranostic                
         4.9. FDA breakthrough therapies: For Companion Diagnostic Tests                
         4.10. Overview FDA approved in-vitro Companion Diagnostic Tests                
         4.11. Companion Diagnostics and regulatory requirements : region  wise                
         4.12. Companion Diagnostic Tests - Intended Diagnostics Type - Market Players     
         4.13. Pipeline Overview: Major market players                

    5. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Detection Technique                 
         5.1. Introduction & Definition                
         5.2. Key Findings / Developments                
         5.3. Key Trends                
         5.4. Market Value Forecast By Detection Technique , 2015–2025                
                5.4.1 Protein Detection                
                         5.4.1.1 Immunohistochemistry                
                5.4.2 DNA Detection                
                         5.4.2.1 Polymerase Chain Reaction                
                         5.4.2.2 Next Gen Sequencing                
                         5.4.2.3 In-Situ Hybridization                
                5.4.3 Others                
         5.5. Market Attractiveness By Detection Technique                 

    6. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Bio-markers                 
         6.1. Introduction & Definition                
         6.2. Key Findings / Developments                
         6.3. Key Trends                     
         6.4. Market Value Forecast By Bio-markers, 2015–2025                
                6.4.1. EGFR                
                6.4.2. KRAS                
                6.4.3. BRAF V600E                
                6.4.4. HER2                
                6.4.5. Others                
         6.5. Market Attractiveness By Bio-markers                 

    7. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Cancer Type                 
         7.1. Introduction & Definition                
         7.2. Key Findings / Developments                
         7.3. Key Trends                
         7.4. Market Value Forecast By Cancer Type , 2015–2025                
                7.4.1 Breast Cancer                
                7.4.2 Liver Cancer                
                7.4.3 Lung Cancer                
                7.4.4 Colorectal Cancer                
                7.4.5 Melanoma                
                7.4.6 Others                 
         7.5. Market Attractiveness By Cancer Type                 

    8. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By End User 
         8.1. Introduction & Definition                
         8.2. Key Findings / Developments                
         8.3. Key Trends                
         8.4. Market Value Forecast By End User , 2015–2025                
                8.4.1 Hospitals                
                8.4.2 Specialty Clinics                
                8.4.3 Diagnostic Labs                
                8.4.4 Others                
         8.5. Market Attractiveness By End User                 

    9. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Region   
         9.1. Key Findings                
         9.2. Policies and Regulations                
         9.3. Market Value Forecast By Region                
                9.3.1 North America                 
                9.3.2 Europe                 
                9.3.3 Asia Pacific                 
                9.3.4 Latin America                 
                9.3.5 Middle East and Africa                 
         9.4. Market Attractiveness By Country/Region                

    10. North America Digital Companion Diagnostics Market  Analysis and Forecast       
         10.1. Introduction                
                10.1.1 Key Findings                
                10.1.2 Policies and Regulations                
                10.1.3 Key Trends                
         10.2. Market Value Forecast By Detection Technique, 2015–2025                
                10.2.1 Protein Detection                
                         10.2.1.1 Immunohistochemistry                
                10.2.2 DNA Detection                
                         10.2.2.1 Polymerase Chain Reaction                
                         10.2.2.2 Next Gen Sequencing                
                         10.2.2.3 In-Situ Hybridization                
                10.2.3 Others                
         10.3. Market Value Forecast By Bio-markers, 2015–2025                
                10.3.1 EGFR                
                10.3.2 KRAS                
                10.3.3 BRAF V600E                
                10.3.4 HER2                
                10.3.5 Others                
         10.4. Market Value Forecast By Cancer Type , 2015–2025                
                10.4.1 Breast Cancer                
                10.4.2 Liver Cancer                
                10.4.3 Lung Cancer                
                10.4.4 Colorectal Cancer                
                10.4.5 Melanoma                
                10.4.6 Others                 
         10.5. Market Value Forecast By End User , 2015–2025                
                10.5.1 Hospitals                
                10.5.2 Specialty Clinics                
                10.5.3 Diagnostic Labs                
                10.5.4 Others                
         10.6. Market Value Forecast By Country , 2015–2025                
                10.6.1 U.S.                
                10.6.2 Canada                
         10.6. Market Attractiveness Analysis                 
                10.6.1 By Detection Technique                 
                10.6.2 By Bio-markers                 
                10.6.3 By Cancer Type                 
                10.6.4 By End User                 
                10.6.5 By Country                

    11. Europe Digital Companion Diagnostics Market  Analysis and Forecast                11.1. Introduction                
                11.1.1 Key Findings                
                11.1.2 Policies and Regulations                
                11.1.3 Key Trends                
         11.2. Market Value Forecast By Detection Technique , 2015–2025                
                11.2.1 Protein Detection                
                         11.2.1.1 Immunohistochemistry                
                11.2.2 DNA Detection                
                         11.2.2.1 Polymerase Chain Reaction                
                         11.2.2.2 Next Gen Sequencing                
                         11.2.2.3 In-Situ Hybridization                
                11.2.3. Others                
         11.3. Market Value Forecast By Bio-markers , 2015–2025                
                11.3.1 EGFR                
                11.3.2 KRAS                
                11.3.3 BRAF V600E                
                11.3.4 HER2                
                11.3.5 Others                
         11.4. Market Value Forecast By Cancer Type , 2015–2025                
                11.4.1 Breast Cancer                
                11.4.2 Liver Cancer                
                11.4.3 Lung Cancer                
                11.4.4 Colorectal Cancer                
                11.4.5 Melanoma                
                11.4.6 Others                 
         11.5. Market Value Forecast By End User , 2015–2025                
                11.5.1 Hospitals                
                11.5.2 Specialty Clinics                
                11.5.3 Diagnostic Labs                
                11.5.4 Others                
         11.6. Market Value Forecast By Country , 2015–2025                
                11.6.1 U.K.                
                11.6.2 Germany                
                11.6.3 France                
                11.6.4 Italy                
                11.6.5 Spain                
                11.6.6 Russia                
                11.6.7 Rest of Europe                
         11.7. Market Attractiveness Analysis                 
                11.7.1 By Detection Technique                 
                11.7.2 By Bio-markers                 
                11.7.3 By Cancer Type                 
                11.7.4 By End User                 
                11.7.5 By Country                

    12. Asia Pacific Digital Companion Diagnostics Market  Analysis and Forecast   12.1. Introduction                
                12.1.1 Key Findings                
                12.1.2 Policies and Regulations                
                12.1.3 Key Trends                
         12.2. Market Value Forecast By Detection Technique , 2015–2025                
                12.2.1 Protein Detection                
                         12.2.1.1 Immunohistochemistry                
                12.2.2 DNA Detection                
                         12.2.2.1 Polymerase Chain Reaction                
                         12.2.2.2 Next Gen Sequencing                
                         12.2.2.3 In-Situ Hybridization                
                12.2.3 Others                
         12.3. Market Value Forecast By Bio-markers , 2015–2025                
                12.3.1 EGFR                
                12.3.2 KRAS                
                12.3.3 BRAF V600E                
                12.3.4 HER2                
                12.3.5 Others                
         12.4. Market Value Forecast By Cancer Type , 2015–2025                
                12.4.1 Breast Cancer                
                12.4.2 Liver Cancer                
                12.4.3 Lung Cancer                
                12.4.4 Colorectal Cancer                
                12.4.5 Melanoma                
                12.4.6 Others                 
         12.5. Market Value Forecast By End User , 2015–2025                
                12.5.1 Hospitals                
                12.5.2 Specialty Clinics                
                12.5.3 Diagnostic Labs                
                12.5.4 Others                
         12.6. Market Value Forecast By Country , 2015–2025                
                12.6.1 India                
                12.6.2 China                
                12.6.3 Japan                
                12.6.4 Australia & New Zealand                
                12.6.5 Rest of Asia Pacific                
         12.7. Market Attractiveness Analysis                 
                12.7.1 By Detection Technique                 
                12.7.2 By Bio-markers                 
                12.7.3 By Cancer Type                 
                12.7.4 By End User                 
                12.7.5 By Country                

    13. Latin America Digital Companion Diagnostics Market  Analysis and Forecast                
         13.1. Introduction                
                13.1.1 Key Findings                
                13.1.2 Policies and Regulations                
                13.1.4 Key Trends                
         13.2. Market Value Forecast By Detection Technique , 2015–2025                
                13.2.1 Protein Detection                
                         13.2.1.1 Immunohistochemistry                
                13.2.2 DNA Detection                
                         13.2.2.1 Polymerase Chain Reaction                
                         13.2.2.2 Next Gen Sequencing                
                         13.2.2.3 In-Situ Hybridization                
                13.2.3 Others                
         13.3. Market Value Forecast By Bio-markers , 2015–2025                
                13.3.1 EGFR                
                13.3.2 KRAS                
                13.3.3 BRAF V600E                
                13.3.4 HER2                
                13.3.5 Others                
         13.4. Market Value Forecast By Cancer Type , 2015–2025                
                13.4.1 Breast Cancer                
                13.4.2 Liver Cancer                
                13.4.3 Lung Cancer                
                13.4.4 Colorectal Cancer                
                13.4.5 Melanoma                
                13.4.6 Others                 
         13.5. Market Value Forecast By End User , 2015–2025                
                13.5.1 Hospitals                
                13.5.2 Specialty Clinics                
                13.5.3 Diagnostic Labs                
                13.5.4. Others                
         13.6. Market Value Forecast By Country , 2015–2025                
                13.6.1 Brazil                
                13.6.2 Mexico                
                13.6.3 Rest of Latin America                
         13.7. Market Attractiveness Analysis                 
                13.7.1 By Detection Technique                 
                13.7.2 By Bio-markers                 
                13.7.3 By Cancer Type                 
                13.7.4 By End User                 
                13.7.5 By Country                

    14. Middle East and Africa Digital Companion Diagnostics Market  Analysis and Forecast                
         14.1. Introduction                
                14.1.1 Key Findings                
                14.1.2 Policies and Regulations                
                14.1.4 Key Trends                
         14.2. Market Value Forecast By Detection Technique , 2015–2025                
                14.2.1 Protein Detection                
                         14.2.1.1 Immunohistochemistry                
                14.2.2 DNA Detection                
                         14.2.2.1 Polymerase Chain Reaction                
                         14.2.2.2 Next Gen Sequencing                
                         14.2.2.3 In-Situ Hybridization                
                14.2.3 Others                
         14.3. Market Value Forecast By Bio-markers , 2015–2025                
                14.3.1 EGFR                
                14.3.2 KRAS                
                14.3.3 BRAF V600E                
                14.3.4 HER2                
                14.3.5 Others                
         14.4. Market Value Forecast By Cancer Type , 2015–2025                
                14.4.1 Breast Cancer                
                14.4.2 Liver Cancer                
                14.4.3 Lung Cancer                
                14.4.4 Colorectal Cancer                
                14.4.5 Melanoma                
                14.4.6 Others                 
         14.5. Market Value Forecast By End User , 2015–2025                
                14.5.1 Hospitals                
                14.5.2 Specialty Clinics                
                14.5.3 Diagnostic Labs                
                14.5.4 Others                
         14.6. Market Value Forecast By Country , 2015–2025                
                14.6.1 South Africa                
                14.6.2 GCC Countries                
                14.6.3 Rest of Middle East and Africa                
         14.7. Market Attractiveness Analysis                 
                14.7.1 By Detection Technique                 
                14.7.2 By Bio-markers                 
                14.7.4 By Cancer Type                 
                14.7.5 By End User                 
                14.7.6 By Country                

    15. Competition Landscape
         15.1 Market Player – Competition Matrix (By Tier and Size of companies)
         15.2 Market Share Analysis By Company (2015)
         15.3 Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                15.3.1 Abbott
                         15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.1.2 Financial Overview
                         15.3.1.3 Product Portfolio
                         15.3.1.4 SWOT Analysis
                         15.3.1.5 Strategic Overview
                15.3.2 F. Hoffman LA Roche Ltd. 
                         15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.2.2 Financial Overview
                         15.3.2.3 Product Portfolio
                         15.3.2.4 SWOT Analysis
                         15.3.2.5 Strategic Overview
                15.3.3 Genomic Health, Inc.
                         15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.3.2 Financial Overview
                         15.3.3.3 Product Portfolio
                         15.3.3.4 SWOT Analysis
                         15.3.3.5 Strategic Overview
                15.3.4 QIAGEN
                         15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.4.2 Financial Overview
                         15.3.4.3 Product Portfolio
                         15.3.4.4 SWOT Analysis
                         15.3.4.5 Strategic Overview
                15.3.5 Agilent Technologies, Inc.
                         15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.5.2 Financial Overview
                         15.3.5.3 Product Portfolio
                         15.3.5.4 SWOT Analysis
                         15.3.5.5 Strategic Overview
                15.3.6 AGENDIA NV
                         15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.6.2 Financial Overview
                         15.3.6.3 Product Portfolio
                         15.3.6.4 SWOT Analysis
                         15.3.6.5 Strategic Overview
                15.3.7 bioMerieux SA
                         15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.7.2 Financial Overview
                         15.3.7.3 Product Portfolio
                         15.3.7.4 SWOT Analysis
                         15.3.7.5 Strategic Overview
                15.3.8 Illumina, Inc.
                         15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.8.2 Financial Overview
                         15.3.8.3 Product Portfolio
                         15.3.8.4 SWOT Analysis
                         15.3.8.5 Strategic Overview
                15.3.9 Siemens Healthcare GmBH
                         15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.9.2 Financial Overview
                         15.3.9.3 Product Portfolio
                         15.3.9.4 SWOT Analysis
                         15.3.9.5 Strategic Overview
                15.3.10 Thermo Fisher Scientific, Inc.
                         15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.10.2 Financial Overview
                         15.3.10.3 Product Portfolio
                         15.3.10.4 SWOT Analysis
                         15.3.10.5 Strategic Overview
                15.3.11 BioGenex
                         15.3.11.1 Company Overview (HQ, Business Segments, Employee Strengths)
                         15.3.11.2 Financial Overview
                         15.3.11.3 Product Portfolio
                         15.3.11.4 SWOT Analysis
                         15.3.11.5 Strategic Overview

    List of Tables

    Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
    Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 06: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
    Table 07: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 09: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
    Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 11: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 12: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 13: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 14: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
    Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 16: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
    Table 17: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 18: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 19: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 20: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 21: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
    Table 22: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 23: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique,
    Table 24: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 25: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 26: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 27: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 28: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
    Table 29: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 30: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
    Table 31: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 32: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 33: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 34: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 35: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
    Table 36: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 37: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
    Table 38: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
    Table 39: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
    Table 40: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
    Table 41: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
    Table 42: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025

    List of Figures

    Figure 01: Global Companion Diagnostic Tests in Oncology, Market Size (US$ Mn) Forecast, 2015–2025
    Figure 02: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type (2016)
    Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker (2016)
    Figure 04: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique (2016)
    Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region (2016)
    Figure 06: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user (2016)
    Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
    Figure 08: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
    Figure 09: Global Protein Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 10: Global DNA Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 11: Global Other Detection Techniques in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
    Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 14: Global Companion Diagnostic Tests in Oncology Market, by EGFR Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 15: Global Companion Diagnostic Tests in Oncology Market, by KRAS Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 16: Global Companion Diagnostic Tests in Oncology Market, by BRAF V600E Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 17: Global Companion Diagnostic Tests in Oncology Market, by HER2 Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 18: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
    Figure 19: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
    Figure 20: Global Companion Diagnostic Tests in Oncology Market, by Breast Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 21: Global Companion Diagnostic Tests in Oncology Market, by Lung Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 22: Global Companion Diagnostic Tests in Oncology Market, by Liver Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 23: Global Companion Diagnostic Tests in Oncology Market, by Colorectal Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 24: Global Companion Diagnostic Tests in Oncology Market, by Melanoma Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 25: Global Companion Diagnostic Tests in Oncology Market, by Other Cancers, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
    Figure 26: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
    Figure 27: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
    Figure 28: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Pharmaceutical & Biotechnology Companies, 2015–2025
    Figure 29: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Medical Device Companies, 2015–2025
    Figure 30: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Research Laboratories, 2015–2025
    Figure 31: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Others, 2015–2025
    Figure 32: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2017 and 2025 
    Figure 33: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Region, 2017–2025
    Figure 34: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Figure 35: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
    Figure 36: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
    Figure 37: North America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
    Figure 38: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
    Figure 39: North America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 40: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 41: North America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
    Figure 42: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
    Figure 43: North America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
    Figure 44: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
    Figure 45: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 46: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
    Figure 47: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
    Figure 48: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
    Figure 49: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
    Figure 50: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 51: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 52: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
    Figure 53: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
    Figure 54: Europe Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
    Figure 55: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
    Figure 56: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 57: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
    Figure 58: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
    Figure 59: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
    Figure 60: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
    Figure 61: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 62: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 63: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
    Figure 64: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
    Figure 65: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
    Figure 66: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
    Figure 67: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 68: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
    Figure 69: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
    Figure 70: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
    Figure 71: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
    Figure 72: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 73: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 74: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
    Figure 75: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
    Figure 76: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
    Figure 77: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
    Figure 78: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
    Figure 79: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025 
    Figure 80: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2017–2025
    Figure 81: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2017 and 2025
    Figure 82: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2017–2025
    Figure 83: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
    Figure 84: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
    Figure 85: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2017 and 2025
    Figure 86: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2017–2025
    Figure 87: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2017 and 2025
    Figure 88: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2017–2025
    Figure 89: Global Companion Diagnostic Tests in Oncology Market Share, by Company, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved